Citizens Maintains Market Outperform on Abivax, Raises Price Target to $187

Benzinga Newsdesk www.benzinga.com Positive 89.9%

Neg 0% Neu 0% Pos 89.9%

Citizens analyst Jason N. Butler maintains Abivax (NASDAQ:ABVX) with a Market Outperform and raises the price target from $131 to $187.